SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is gaining significant community attention as traders discuss a potential breakout from its consolidation channel, with many pointing to upward momentum and comparisons to other fintech platforms as key drivers. Active discussion centers on price action near resistance levels, analyst upgrades, and the ongoing tug-of-war between optimistic bulls expecting a squeeze and skeptics wary of previous failed rallies.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending as investors debate whether the stock's recent price consolidation represents a deep value opportunity ahead of earnings or a long-term decline in market share. The community is actively tracking potential institutional accumulation and short interest while speculating on the impact of Pepsi's distribution and the performance of newer product lines.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending as positive regulatory momentum surrounding the CLARITY Act and the rising price of Bitcoin drive a technical breakout on heavy volume. The community is actively debating whether this move signals a sustainable reversal or a bull trap, with many traders closely tracking the stock's performance against key resistance levels.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus and massive trading volume following a new international defense contract, sparking heavy debate over a potential short squeeze and the company's long-term growth prospects. The community remains sharply divided between bulls citing the strong defense backlog and technical support levels, and bears pointing to ongoing dilution and negative sentiment as reasons for the stock's recent volatility.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as high volume and unusual institutional activity fuel a technical breakout, with community members actively discussing a potential short squeeze and high-growth potential ahead of key clinical data readouts. Investors are particularly focused on the upcoming NSCLC pipeline updates, citing deep institutional accumulation and ongoing speculation about a potential strategic partnership or acquisition as key drivers for the current upward momentum.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is experiencing high volatility as investors weigh the company's strong Q2 revenue beat and positive long-term AI power infrastructure thesis against concerns regarding the sustainability of its recent rapid price run-up. The community remains deeply divided, with some traders aggressively shorting the stock citing rich valuations, while bulls continue to accumulate, betting on the long-term potential of the firm's proprietary power delivery technology within the AI data center supply chain.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is currently trading in the spotlight as investors track the commercial rollout of ZEVASKYN, particularly following the activation of its seventh Qualified Treatment Center, Cincinnati Children's. The community is actively debating the company's long-term potential, focusing on commercial execution, low debt levels, and the anticipated 'snowball effect' of patient onboarding, while others express frustration over share price volatility and the pace of treatment uptake.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as investors react to the company's recent Phase 3 trial enrollment milestone and broader optimism surrounding potential federal policy shifts in the psychedelic biotech sector. The community is actively debating the stock's future, balancing enthusiasm for the company's clinical progress against concerns regarding management turnover and historical dilution.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending following disclosure that Michael Burry has established a significant long position in the stock, signaling investor confidence that the company is reaching a positive operating inflection point. Community sentiment remains polarized, with many longs optimistic that regulated growth and sports betting catalysts will drive long-term value, while critics continue to debate the impact of prediction markets and historical stock performance.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is trending following a beat-and-raise earnings performance that outperformed market expectations, though shares faced immediate volatility as investors grappled with increased capital expenditure tied to the B-21 program. The community is actively debating the company's valuation against the broader defense sector, with many focusing on its deep backlog, strategic importance to U.S. defense modernization, and the long-term potential for a rebound driven by rising geopolitical tensions and military spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tuesday Sector Leaders: Drugs, Gas Utilities

In trading on Tuesday, drugs shares were relative leaders, up on the day by about 2%. Leading the group were shares of Crinetics Pharmaceuticals, up about 98.8% and shares of Pyxis Oncology up about 18.7% on the day.

Also showing relative strength are gas utilities shares, up...

Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7%

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,269,065 shares, a drop of 14.7% from the March 31st total of 2,660,931 shares. Approximately 4.0% of the company's stock are...

Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research report on Monday...

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...

Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Wall Street Zen lowered Pyxis Oncology from a "hold" rating to a "sell" rating in a report on Sunday...

Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...

Rachel Humphrey Sells 13,896 Shares of Pyxis Oncology (NASDAQ:PYXS) Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of...

Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Pyxis Oncology in a report issued on Tuesday, March...

Pyxis Oncology (NASDAQ:PYXS) Director Rachel Humphrey Sells 13,896 Shares

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) Director Rachel Humphrey sold 13,896 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average...

FY2029 EPS Estimates for Pyxis Oncology Lifted by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at HC Wainwright upped their FY2029 earnings per share estimates for shares of Pyxis Oncology in a research report issued on Tuesday, March...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Pyxis Oncology Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PYXSPyxis Oncology Inc

Fundamentals

Latest PYXS News